CAS 862502-26-9: L-Threonine,N-(1-oxotetradecyl)-L-seryl-L-leucyl-L-asparaginyl-L-prolyl-L-a-glutamyl-L-tryptophyl-L-asparaginyl-L-a-glutamyl- (9CI)

PKCβII Peptide Inhibitor I, a specific PKCβII inhibitor, exhibits cardioprotective properties in a rat cardiac ischemia/reperfusion injury model and mitigates

Pkcβii peptide inhibitor I trifluoroacetate salt is a specific peptide inhibitor that targets the protein kinase C beta II (PKCβII) isoform. This inhibitor is commonly sourced from synthetic peptide libraries and is integrated with trifluoroacetate as a counterion to enhance stability and solubility. The mode of action involves the selective inhibition of PKCβII, interfering with its role in cellular signaling pathways. As PKCβII is implicated in the regulation of various cellular processes such as growth, differentiation, and apoptosis, the inhibitor is valuable for elucidating the mechanistic roles of this kinase in cellular physiology and pathophysiology.The Pkcβii peptide inhibitor I trifluoroacetate salt is primarily utilized in biochemical and cellular research to investigate the specific pathways mediated by PKCβII. Its applications extend to studies involving cancer research, diabetes, cardiovascular diseases, and other conditions where PKCβII's activity is a contributing factor. By enabling precise inhibition, researchers can dissect the isoform-specific effects and potentially tailor therapeutic strategies, thus advancing the understanding of PKCβII's function in health and disease.